Metastasis pp 310-314 | Cite as

Minimal Residual Disease May be Treated by Chessboard Vaccination with Vibrio Cholerae Neuraminidase (VCN) and Tumor Cellss

  • H. H. Sedlacek
  • H. J. Bengelsdorff
  • R. Kurrle
  • F. R. Seiler
Part of the Developments in Oncology book series (DION, volume 4)


Vibrio cholerae neuraminidase (VCN) has been shown to have an adjuvant effect predominantly for the cellular immune response when admixed with a variety of antigens. On the basis of these findings, the therapeutic effect of specific immunotherapy with the use of VCN was evaluated on the growth of metastases of Lewis lung adenocarcinoma in C57B1/6 mice. Tumor immunotherapy was performed after complete excision of the primary tumor graft and after an adapted chemotherapy (cyclophosphamide) by intradermal injection of increasing numbers of tumor cells (105 – 107) mixed with increasing amounts of VCN (0–65 mU). This procedure has already been described as “chessboard vaccination”.

Such treatment reduced the number of animals that died due to metastasis. In contrast, subcutaneous injection of VCN-treated but subsequently washed tumor cells had no effect. In therapeutic studies in dogs suffering from spontaneous breast tumors, the s.c. injection of VCN-treated cells had, depending on the cell dose, either a therapeutical effect or no effect at all (low dose), or even an enhancing effect on tumor growth (high dose). With the chessboard vaccination procedure, how ever, a therapeutic effect could be seen which was not cell dose dependent. Thus, chessboard vaccination, which has less risk of inducing tumor enhancement, may be recommended for tumor immunotherapy.


Acute Myeloid Leukemia Minimal Residual Disease Intradermal Injection Cell Dose Specific Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bekesi, J.G., Holland, J.F., 1979. In: R. Neth, R.C. Gallo et al. (Editors), Modern Trends in Human Leukemia III, Springer-Verlag, Berlin, pp. 79–87.CrossRefGoogle Scholar
  2. Mackaness, G.B., Lagrange, P.H., Miller, T.E., Ishibashi, T., 1974. In: W.N. Wagner, H. Hahn, R. Evans (Editors), Activation of Macrophages, Excerpta Medica, Amsterdam, pp. 193–209.Google Scholar
  3. Ronneberger, H., 1978. Develop. biol. Standard. 38, 413–419.Google Scholar
  4. Schick, H.J., Zilg, H. 1978. Develop. biol. Standrd. 38, 81–85.Google Scholar
  5. Schneider, D.R., Sedlacek, H.H., Seiler, F.R., 1979. In: R. Schauer, P. Boer, et al. (Editors), Glycoconjugates, G. Thieme Verlag, Stuttgart, pp. 354–355.Google Scholar
  6. Sedlacek, H.H., Meesmann, H., Seiler, F.R., 1975. Int. J. Cancer 15, 409–416.PubMedCrossRefGoogle Scholar
  7. Sedlacek, H.H., Seiler, F.R., 1978. Cancer Immunol. Immunother. 5, 153–163.CrossRefGoogle Scholar
  8. Sedlacek, H.H., Weise, M., Lemmer, A., Seiler, F.R., 1979. Cancer Immunol. Immunother. 6, 57–58.CrossRefGoogle Scholar
  9. Seiler, -, F.R., Sedlacek, H.H., 1974. Behring Inst. Mitt. No. 55, 258–271.Google Scholar
  10. Seiler, F.R., Sedlacek, H.H., 1978. Proc. Symp. Immunother. of Malignant Diseases, Schattauer-Verlag, Stuttgart, pp. 479–488.Google Scholar
  11. Wilson, R.E., Sonis, S.T., Godrick, E.A., 1974. Behring Inst. Mitt. No. 55, 334–342.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1980

Authors and Affiliations

  • H. H. Sedlacek
  • H. J. Bengelsdorff
  • R. Kurrle
  • F. R. Seiler

There are no affiliations available

Personalised recommendations